Japan’s Special Re-Pricing Rules to Hit 17 Drugs in April; Potentially Big Slash for Keytruda, Lixiana

Japan’s health ministry on January 22 unveiled a list of 17 drugs (APIs) that will be subject to its special re-pricing rules this April. While their price reduction rates will not be disclosed until early March, fast-growing Keytruda (pembrolizumab) and...read more